Literature DB >> 22948659

Pancreatic carcinoma cell lines reflect frequency and variability of cancer stem cell markers in clinical tissue.

S Bünger1, M Barow, C Thorns, S Freitag-Wolf, S Danner, S Tiede, R Pries, S Görg, H-P Bruch, U J Roblick, C Kruse, J K Habermann.   

Abstract

BACKGROUND: Pancreatic cancer is one of the most deadly malignancies with insufficient therapeutic options and poor outcome. Cancer stem cells (CSCs) are thought to be responsible for progression and therapy resistance. We investigated the potential of pancreatic cell lines for CSC research by analyzing to what extent they contain CSC populations and how representative these are compared to clinical tissue.
METHODS: Six pancreatic cancer cell lines were analyzed by flow cytometry for CD326, CD133, CD44, CD24, CXCR4 and ABCG2. Subsequently, 70 primary pancreatic tissues were evaluated for CD326, CD133 and CD44 by immunohistochemistry.
RESULTS: All the cell lines but one showed a stable expression pattern throughout biological replicates. Marker expression in clinical tissue of CD44 distinguished normal patients from pancreatic carcinoma patients with a sensitivity of 50% at 80% specificity and metastasized from nonmetastasized carcinomas with 69% sensitivity at 100% specificity.
CONCLUSIONS: Our results indicate a link between elevated CD44 expression, malignancy and metastasis of pancreatic tissue. Furthermore, individual pancreatic cell lines show a substantial amount of cells with CSC properties which is comparable with interpatient variability detected in primary tissue. These pancreatic cancer cell lines could thus serve for urgently needed pharmacological CSC in vitro research.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948659     DOI: 10.1159/000341669

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  11 in total

1.  Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma.

Authors:  S M Adnan Ali; Yumna Adnan; Saleema Mehboob Ali; Zubair Ahmad; Tabish Chawla; Hasnain Ahmed Farooqui
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-06       Impact factor: 4.322

2.  Formulation Comprising Arsenic Trioxide and Dimercaprol Enhances Radiosensitivity of Pancreatic Cancer Xenografts.

Authors:  Renyan Tang; Jianmin Zhu; Ying Liu; Ning Wu; Jinbin Han
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

Review 3.  Biomarkers for predicting future metastasis of human gastrointestinal tumors.

Authors:  Lui Ng; Ronnie Tung Ping Poon; Roberta Pang
Journal:  Cell Mol Life Sci       Date:  2013-01-31       Impact factor: 9.261

Review 4.  Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells.

Authors:  Susmita Barman; Iram Fatima; Amar B Singh; Punita Dhawan
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

5.  SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.

Authors:  Yu-Wen Chen; Pi-Jung Hsiao; Ching-Chieh Weng; Kung-Kai Kuo; Tzu-Lei Kuo; Deng-Chyang Wu; Wen-Chun Hung; Kuang-Hung Cheng
Journal:  BMC Cancer       Date:  2014-03-14       Impact factor: 4.430

6.  Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma.

Authors:  Jan Skoda; Marketa Hermanova; Tomas Loja; Pavel Nemec; Jakub Neradil; Petr Karasek; Renata Veselska
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

7.  Progressively De-Differentiated Pancreatic Cancer Cells Shift from Glycolysis to Oxidative Metabolism and Gain a Quiescent Stem State.

Authors:  Giulia Ambrosini; Elisa Dalla Pozza; Giuseppina Fanelli; Claudia Di Carlo; Andrea Vettori; Giuseppe Cannino; Chiara Cavallini; Cristian Andres Carmona-Carmona; Jessica Brandi; Sara Rinalducci; Maria Teresa Scupoli; Andrea Rasola; Daniela Cecconi; Marta Palmieri; Ilaria Dando
Journal:  Cells       Date:  2020-06-28       Impact factor: 6.600

8.  DEspR roles in tumor vasculo-angiogenesis, invasiveness, CSC-survival and anoikis resistance: a 'common receptor coordinator' paradigm.

Authors:  Victoria L Herrera; Julius L Decano; Glaiza A Tan; Ann M Moran; Khristine A Pasion; Yuichi Matsubara; Nelson Ruiz-Opazo
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

9.  Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.

Authors:  Tatsuzo Mizukami; Hirofumi Kamachi; Tomoko Mitsuhashi; Yosuke Tsuruga; Yutaka Hatanaka; Toshiya Kamiyama; Yoshihiro Matsuno; Akinobu Taketomi
Journal:  BMC Cancer       Date:  2014-09-21       Impact factor: 4.430

10.  Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting.

Authors:  Pablo Hernández-Camarero; Elena López-Ruiz; Carmen Griñán-Lisón; María Ángel García; Carlos Chocarro-Wrona; Juan Antonio Marchal; Julian Kenyon; Macarena Perán
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.